We want to bring this protoype, now at TRL3, to the market. We are looking for:

(1) public/private investors, to further develop the system up to TRL6 in 3 years from now.

(2) partners in the pharma industry, to validate our solution in a relevant environment and

adapt it to the real market needs

Current stage: (i) We have developed the microscope at TRL6 for bioimaging of cells and tissues in transmission in the framework of the CRIMSON project. (ii) We have identified a potential market with very large addressable market: quality control of pharma tablets in production line.

Next steps: (i) We will redesign the prototype for mapping solid pharma tablets in backscattering (epi) configuration, thus (re-)starting at TRL3. (ii) We will perform market, competitor landscape and freedom to operate analyses to compile a convincing business plan. (iii) We will team up with potential future customers in the pharma industry, to validate our solution.

Our business model is scalable because we can engineer the production line of the device, keeping high quality standards, to respond to a future increase in its demand, while facing competition and remaining profitable.

Our future product will be manufactured following ISO standard procedures and the “Good Automated Manufacturing Practice” (GAMP) set out by the International Society for Pharmaceutical Industry. This will guarantee the replicability of the device to meet the required specification, in order to sell it consistently and reliably.